Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics (Nasdaq: DNTH) announced it will participate in the 44th Annual J.P.

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Marino Garcia will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST and will hold one-on-one investor meetings.

A webcast of the presentation will be available in the company’s Investors section under “News and Events.” The announcement highlights investor access opportunities but does not provide financial or clinical data in this release.

Argus Jan 5 session

-7.03% close to close Open Argus

Details

News Market Reaction – DNTH

On Jan 5, the day this news came out, DNTH closed 7.03% below the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Market Context

On Jan 5, the day this news came out, the stock closed 7.0% below the previous close. A negative rea...

Analysis

On Jan 5, the day this news came out, the stock closed 7.0% below the previous close. A negative reaction despite neutral conference participation fits periods where the stock moved counter to generally constructive news, such as earlier clinical updates. Conference announcements typically provide visibility rather than new fundamentals, so traders may fade such catalysts. Prior equity financing and typical biotech funding needs remain background risks that can weigh on sentiment, even when no new clinical or financial data accompany an appearance update.

Key Figures

Conference edition: 44th Presentation date: January 12, 2026 Presentation time PST: 3:00 p.m. PST +1 more

Conference edition

44th

44th Annual J.P. Morgan Healthcare Conference

Presentation date

January 12, 2026

Scheduled corporate overview presentation

Presentation time PST

3:00 p.m. PST

J.P. Morgan Healthcare Conference presentation slot

Presentation time EST

6:00 p.m. EST

J.P. Morgan Healthcare Conference presentation slot

Historical Context

5 past events · Latest: Dec 23

5 events

1. Dec 23

   Clinical trial start

   24h Move

   -2.6%

   Initiation and first dosing in Phase 1 LBL-047 (DNTH212) trial.

2. Nov 24

   Investor conference

   24h Move

   +5.4%

   Participation in Evercore healthcare conference with fireside chat and meetings.

3. Nov 05

   Earnings and update

   24h Move

   +1.6%

   Q3 2025 results and positive updates on claseprubart and DNTH212.

4. Nov 04

   Multiple conferences

   24h Move

   -2.4%

   Announcement of participation in four investor conferences in November.

5. Oct 29

   Clinical data update

   24h Move

   +0.5%

   New Phase 2 MaGic and preclinical claseprubart data at AANEM meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the 44^th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors.

A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Dianthus Therapeutics (DNTH) present at the J.P. Morgan Healthcare Conference?

Dianthus will present on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST.

Who from Dianthus Therapeutics (DNTH) will present at the January 2026 J.P. Morgan conference?

Marino Garcia, CEO of Dianthus Therapeutics, will deliver the corporate overview.

How can investors watch the Dianthus Therapeutics (DNTH) presentation from J.P. Morgan 2026?

A webcast will be available under News and Events in the Investors section of the Dianthus Therapeutics website.

Will Dianthus Therapeutics (DNTH) hold investor meetings at the J.P. Morgan conference?

Yes, the CEO will host one-on-one meetings with investors during the conference.

What topics will Dianthus Therapeutics (DNTH) cover in the January 12, 2026 presentation?

The company announced a corporate overview; no further presentation details were provided in the announcement.

Where is the 44th Annual J.P. Morgan Healthcare Conference being held for the DNTH presentation?

The conference is taking place in San Francisco.